SUPN FY 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$520M+32.5% YoY

Gross Profit

$468M89.9% margin

Operating Income

$174M33.4% margin

Net Income

$127M24.4% margin

EPS (Diluted)

$2.36

Cash Flow

Operating Cash Flow

$138M

Free Cash Flow

$135M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$759M

Stockholders' Equity

$745M

Cash & Equivalents

$289M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$520M	$393M	+32.5%
Gross Profit	$468M	$376M	+24.4%
Operating Income	$174M	$149M	+16.9%
Net Income	$127M	$113M	+12.3%